Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

Core Insights - Bayer has initiated a Phase IIa clinical trial for BAY 3401016, a monoclonal antibody targeting Semaphorin 3A, which is linked to kidney damage in Alport Syndrome [1] Group 1 - The clinical trial, named ASSESS, is a randomized, double-blind, placebo-controlled study [1] - The trial includes an extension phase to further investigate the effects of BAY 3401016 [1] - Alport Syndrome is identified as a rare genetic disorder that leads to kidney damage [1]